Best Chronic Myeloid Leukemia Podcasts (2025)

1
Key Advances in Lymphomas and Acute Lymphocytic Leukemia From EHA and ICML 2025 39:12

13h ago39:12

39:12

In this podcast, Max S. Topp, MD, and Pier Luigi Zinzani, MD, PhD, explore the current and future implications of some of their top choices of studies in lymphomas and ALL presented at the EHA and ICML 2025 meetings. Program Abstracts: POLARGO: Rituximab, Gemcitabine and Oxaliplatin ± Polatuzumab Vedotin for R/R DLBCL ECHO: Rituximab-Bendamustine ±…

1
Experts Discuss Key Studies in Breast Cancer: Independent Conference Coverage of the 2025 ASCO Annual Meeting 35:02

4d ago35:02

35:02

In this episode, Kevin Kalinsky, MD, MS, FASCO, and Sara M. Tolaney, MD, MPH, discuss the most clinically relevant data in breast cancer presented at the 2025 ASCO Annual Meeting, including: DESTINY-Breast09: phase III trial of trastuzumab deruxtecan with or without pertuzumab vs THP as first-line treatment of HER2-positive advanced/metastatic brea…

1
Takeaways From a Large Educational Program on Available and Emerging Treatment Options for HER2-Positive mBC 18:04

4d ago18:04

18:04

In this episode, listen to Laura M. Spring, MD; and Shipra Gandhi, MD, MS, share their takeaways from a large educational program on available and emerging first-line treatment options for patients with HER2-positive mBC: Emerging new data from the phase IIII DESTINY-Breast09 trial of first-line treatment with trastuzumab deruxtecan ± pertuzumab vs…

1
A New Revolution in AML Treatment: Can Menin Inhibitors Follow the Path of FLT3 and IDH Inhibitors? 22:23

5d ago22:23

22:23

In this episode, Eunice Wang, MD and Eytan Stein, MD explore the latest key clinical updates on menin inhibitors in AML. This episode unpacks evolving treatment strategies and what these developments mean for patient care. Presenters: Eytan M. Stein, MD Chief, Leukemia Service Director, Program for Drug Development in Leukemia Associate Attending P…

1
BTK Inhibitors in CLL: Key Clinical Updates From ASCO & EHA 2025 21:24

6d ago21:24

21:24

In this episode, James Davis, PharmD, BCOP and Victoria Nachar, PharmD, BCOP summarize the latest key clinical updates on BTK inhibitors in CLL based on data recently presented at the annual ASCO and EHA meetings, including: The randomized phase III FLAIR trial The randomized phase III SEQUOIA trial The randomized phase III BRUIN CLL-321 trial Pres…

1
Chronic Lymphocytic Leukemia — Proceedings from a Session Held During the 2025 ASCO Annual Meeting 1:00:43

7d ago1:00:43

1:00:43

Dr Catherine Coombs and Dr William Wierda summarize major treatment advances in chronic lymphocytic leukemia presented at the 2025 American Society of Clinical Oncology Annual Meeting and review ongoing clinical trials. CME information and select publications here.By Dr. Neil Love

1
Incorporating Immune Checkpoint Inhibitors Across the Disease Spectrum of Hepatocellular Carcinoma 31:19

11d ago31:19

31:19

In this episode, Joseph W. Franses, MD, PhD; Neehar Parikh, MD, MS; and Mark Yarchoan, MD, share their thoughts on incorporating immune checkpoint inhibitors into the care of patients with HCC including: Clinical Considerations for Selecting First-line Immunotherapy Combinations for Metastatic HCC Overview of the Latest Data for the Combination of …

1
Personalized Pathways: Redefining Frontline Hodgkin Lymphoma Treatment Strategies 35:36

11d ago35:36

35:36

In this episode, Jonathan W. Friedberg, MD; Alex F. Herrera, MD; and Kara Kelly, MD, discuss the latest frontline treatment options for advanced Hodgkin lymphoma (HL) and approaches to personalizing treatment for the general patient population, older patients, and pediatric patients. This podcast was adapted from a live presentation held in May 202…

1
Ovarian Cancer — An Interview with Ms Jennifer Filipi on the Current Treatment Paradigm and New Approaches 53:51

12d ago53:51

53:51

Ms Jennifer Filipi from the Massachusetts General Hospital Cancer Center in Boston discusses nursing considerations for the treatment of ovarian cancer. NCPD information and select publications here.By Dr. Neil Love

1
Multiple Myeloma — Proceedings from a Webinar Held in Conjunction with the 2025 ASCO Annual Meeting 58:41

12d ago58:41

58:41

Dr Ajay K Nooka from Winship Cancer Institute of Emory University in Atlanta, Georgia, and Dr Paul G Richardson from Dana-Farber Cancer Institute in Boston, Massachusetts, discuss recent updates on available and novel treatment strategies for multiple myeloma. CME information and select publications here.…

1
Experts Discuss CELMoDs in Myeloma 35:51

14d ago35:51

35:51

In this episode, Jesus Berdeja, MD; Amrita Krishnan, MD, FACP; and Sagar Lonial, MD, FACP, discuss key topics with CELMoD therapy for multiple myeloma, including: Mechanistic differences between CELMoDs and IMiDs Emerging data with CELMoDs and their potential therapeutic roles across the disease continuum of multiple myeloma The clinical implicatio…

1
For Oncology Nurses: Chronic Lymphocytic Leukemia — Proceedings from the 2025 Annual ONS Congress 1:30:22

16d ago1:30:22

1:30:22

Dr Bita Fakhri, Dr Jeff Sharman, and nurse practitioners Dr Jacqueline Broadway-Duren and Ms Corinne Hoffman discuss the current treatment landscape for chronic lymphocytic leukemia and strategies to mitigate and manage treatment-emergent adverse events. NCPD information and select publications here.…

1
Chronic Lymphocytic Leukemia — Proceedings from the 2025 Annual ONS Congress 1:30:22

19d ago1:30:22

1:30:22

Dr Bita Fakhri, Dr Jeff Sharman, and nurse practitioners Dr Jacqueline Broadway-Duren and Ms Corinne Hoffman discuss the current treatment landscape for chronic lymphocytic leukemia and strategies to mitigate and manage treatment-emergent adverse events. NCPD information and select publications here.…

1
Non-Hodgkin Lymphoma — Proceedings from a Session Held During the 2025 ASCO Annual Meeting 1:59:42

20d ago1:59:42

1:59:42

Dr Jeremy Abramson from Massachusetts General Hospital in Boston, Dr Joshua Brody from the Tisch Cancer Institute in New York, New York, Dr Christopher Flowers from The University of Texas MD Anderson Cancer Center in Houston, Dr Ann LaCasce from Dana-Farber Cancer Institute in Boston, Massachusetts, and Dr Tycel Phillips from City of Hope Comprehe…

1
DLL3-Targeting Bispecific T-Cell Engagers for Small Cell Lung Cancer — Proceedings from the 2025 Annual ONS Congress 1:27:39

23d ago1:27:39

1:27:39

Dr Anne Chiang, Dr Erin Schenk, and nurse practitioners Ms Elizabeth Krueger and Ms Beth Sandy discuss the role of bispecific antibodies in the management of small cell lung cancer and strategies to mitigate and manage treatment-emergent adverse events. NCPD information and select publications here.By Dr. Neil Love

1
For Oncology Nurses: Non-Hodgkin Lymphoma — Proceedings from the 2025 Annual ONS Congress 1:26:53

25d ago1:26:53

1:26:53

Dr Christopher Flowers and Dr Manali Kamdar summarize the clinical treatment landscape for patients with non-Hodgkin lymphoma, supported by clinical perspectives and management strategies from nurse practitioners Ms Robin Klebig and Ms Caitlin Murphy. NCPD information and select publications here.By Dr. Neil Love

1
Non-Hodgkin Lymphoma — Proceedings from the 2025 Annual ONS Congress 1:26:53

26d ago1:26:53

1:26:53

Dr Christopher Flowers and Dr Manali Kamdar summarize the clinical treatment landscape for patients with non-Hodgkin lymphoma, supported by clinical perspectives and management strategies from nurse practitioners Ms Robin Klebig and Ms Caitlin Murphy. NCPD information and select publications here.By Dr. Neil Love

1
For Oncology Nurses: Chronic Myeloid Leukemia — Proceedings from the 2025 Annual ONS Congress 1:26:22

1M ago1:26:22

1:26:22

Dr Michael Mauro, Dr Neil Shah, and nurse practitioners Ms Ilene Galinsky and Dr Sara Tinsley-Vance discuss important nursing considerations in the modern treatment of chronic myeloid leukemia. NCPD information and select publications here.By Dr. Neil Love

1
Chronic Myeloid Leukemia — Proceedings from the 2025 Annual ONS Congress 1:26:22

1M ago1:26:22

1:26:22

Dr Michael Mauro, Dr Neil Shah, and nurse practitioners Ms Ilene Galinsky and Dr Sara Tinsley-Vance discuss important nursing considerations in the modern treatment of chronic myeloid leukemia. NCPD information and select publications here.By Dr. Neil Love

1
IDH-Mutant Low-Grade Glioma — An Interview with Dr Patrick Y Wen on Current and Future Management Strategies 54:07

1M ago54:07

54:07

Dr Patrick Wen from the Dana-Farber Cancer Institute in Boston, Massachusetts, discusses the current and future management of IDH-mutant gliomas. CME information and select publications here.By Dr. Neil Love

1
Multiple Myeloma — Year in Review Series on Relevant New Datasets and Advances 59:09

1M ago59:09

59:09

Prof Meletios-Athanasios (Thanos) C Dimopoulos from the National and Kapodistrian University of Athens and Alexandra Hospital in Athens, Greece, and Dr Robert Z Orlowski from The University of Texas MD Anderson Cancer Center in Houston, Texas, provide their perspectives on relevant new clinical data in multiple myeloma and their application to dise…

1
Hormone Receptor-Positive Breast Cancer — Proceedings from the 2025 Annual ONS Congress 1:54:49

1M ago1:54:49

1:54:49

Drs Virginia F Borges and Seth Wander summarize the treatment landscape for patients with hormone receptor-positive breast cancer, supported with clinical perspectives and management strategies from nurse practitioners Ms Jamie Carroll and Mr Ronald Stein. NCPD information and select publications here.…

1
Gastroesophageal Cancer — Proceedings from the 2025 Annual ONS Congress 1:29:49

2M ago1:29:49

1:29:49

Dr Sunnie Kim and Dr Manish Shah summarize the clinical treatment landscape for patients with gastroesophageal cancers, supported by clinical perspectives and management strategies from oncology nursing experts Ms Brooke Parker and Ms Michal Segal. NCPD information and select publications here.By Dr. Neil Love

1
Myelofibrosis — Year in Review Series on Relevant New Datasets and Advances 59:18

2M ago59:18

59:18

Professor Claire Harrison from the Guy’s and St Thomas’ NHS Foundation Trust in London, United Kingdom, and Dr John Mascarenas from The Tisch Cancer Institute in New York, New York, provide their perspectives on relevant new clinical data in myelofibrosis and discuss their application to treatment. CME information and select publications here.…

1
Endometrial Cancer — Proceedings from the 2025 Annual ONS Congress 1:28:47

2M ago1:28:47

1:28:47

Dr Ritu Salani and Dr Brian Slomovitz and nurse practitioners Ms Kathryn Lyle and Ms Jaclyn Shaver discuss datasets guiding treatment decision-making for patients with endometrial cancer and strategies to mitigate and manage treatment-emergent adverse events. NCPD information and select publications here.…

1
Non-Hodgkin Lymphoma — Year in Review Series on Relevant New Datasets and Advances 59:08

2M ago59:08

59:08

Dr Stephen Ansell from Mayo Clinic in Rochester, Minnesota, and Dr Brian Hill from Cleveland Clinic Taussig Cancer Institute in Ohio summarize major treatment advances over the past year and review relevant ongoing clinical trials for patients with non-Hodgkin lymphoma. CME information and select publications here.…

1
Systemic Mastocytosis and Myelofibrosis — Fourth Annual National General Medical Oncology Summit 47:55

2M ago47:55

47:55

Clinical investigators discuss available data guiding the management of systemic mastocytosis and myelofibrosis.  CME information and select publications here.By Dr. Neil Love

1
Multiple Myeloma — Fourth Annual National General Medical Oncology Summit 50:41

2M ago50:41

50:41

Clinical investigators discuss available data guiding the management of multiple myeloma.  CME information and select publications here.By Dr. Neil Love

1
Pancreatic Cancer — Proceedings from the 2025 Annual ONS Congress 1:33:16

2M ago1:33:16

1:33:16

Drs Farshid Dayyani and Philip A Philip and oncology nursing professionals Caroline Kuhlman and Amanda K Wagner discuss datasets guiding treatment decision-making for patients with metastatic pancreatic cancer and strategies to mitigate and manage treatment-emergent adverse events. NCPD information and select publications here.…

1
Role of the Multidisciplinary Team in Achieving Comprehensive and Individualized Care of Patients with HR-positive/HER2-negative Metastatic Breast Cancer and Preexisting Comorbidities 35:15

2M ago35:15

35:15

In this podcast episode, Sara A. Hurvitz, MD, FACP, La-Urshalar B. Brock, FNP-BC, CNM, and Jordan Hill, PharmD, BCOP, discuss the important role of the multidisciplinary team in achieving comprehensive and individualized care of patients with HR-positive/HER2-negative metastatic breast cancer and preexisting comorbidities, including: Key Comorbidit…

1
Multiple Myeloma — An Interview with Dr Rafael Fonseca on Key Presentations from the 66th American Society of Hematology (ASH) Annual Meeting 50:50

2M ago50:50

50:50

Dr Rafael Fonseca from Mayo Clinic in Phoenix, Arizona, discusses datasets from the 2024 ASH meeting on the management of newly diagnosed and relapsed/refractory multiple myeloma. CME information and select publications here.By Dr. Neil Love

1
Chronic Lymphocytic Leukemia — An Interview with Dr Lindsey Roeker on Key Presentations from the 66th American Society of Hematology (ASH) Annual Meeting 48:22

2M ago48:22

48:22

Dr Lindsey Roeker from Mayo Clinic in Rochester, Minnesota, discusses recent updates on available and novel treatment strategies for chronic lymphocytic leukemia. CME information and select publications here.By Dr. Neil Love

1
Relapsed/Refractory Follicular Lymphoma Part 3 — A Roundtable Discussion on the Selection and Sequencing of Other Novel Therapies 42:34

2M ago42:34

42:34

Dr Carla Casulo from Wilmot Cancer Institute in Rochester, New York, Dr Matthew Matasar from Rutgers Cancer Institute of New Jersey in New Brunswick and Dr Laurie H Sehn from BC Cancer Centre for Lymphoid Cancer in Vancouver discuss recent updates on available and novel treatment strategies for relapsed/refractory follicular lymphoma. CME informati…

1
Non-Hodgkin Lymphoma — An Interview with Dr Jennifer Crombie on the Use of Bispecific Antibodies 49:54

2M ago49:54

49:54

Dr Jennifer Crombie from the Dana-Farber Cancer Institute in Boston, Massachusetts, reviews available and investigational CD20 x CD3 targeted bispecific antibodies for the treatment of follicular and diffuse large B-cell lymphomas. CME information and select publications here.By Dr. Neil Love

1
Relapsed/Refractory Follicular Lymphoma Part 2 — A Roundtable Discussion on the Selection and Sequencing of CAR T-Cell Therapy 37:08

2M ago37:08

37:08

Dr Carla Casulo from Wilmot Cancer Institute in Rochester, New York, Dr Matthew Matasar from Rutgers Cancer Institute of New Jersey in New Brunswick and Dr Laurie H Sehn from BC Cancer Centre for Lymphoid Cancer in Vancouver discuss recent updates on available and novel treatment strategies for relapsed/refractory follicular lymphoma. CME informati…

1
Uncovering Safety and Signposts to the Future: AEs With HER2-Targeted ADCs and Future Applications 21:54

2M ago21:54

21:54

In this episode, Catherine Fahey, MD, PhD; Alexandra Leary, MD, PhD; Funda Meric-Bernstam, MD; and Zev A. Wainberg, MD, discuss the evolving safety considerations and future directions of HER2-targeted antibody–drug conjugates (ADCs) across genitourinary, gastrointestinal, and gynecologic cancers. Toxicity Profiles of HER2-Targeted ADCs: Common and…

1
Non-Hodgkin Lymphoma — Fourth Annual National General Medical Oncology Summit 50:03

3M ago50:03

50:03

Clinical investigators discuss available data guiding the management of non-Hodgkin lymphoma.  CME information and select publications here.By Dr. Neil Love

1
Non-Hodgkin Lymphoma — An Interview with Dr John P Leonard on Key Presentations from the 66th American Society of Hematology (ASH) Annual Meeting 52:36

3M ago52:36

52:36

Dr John P Leonard from Weill Cornell Medicine in New York, New York, reviews data presented at the 2024 ASH Annual Meeting and their implications for the treatment of non-Hodgkin lymphomas. CME information and select publications here.By Dr. Neil Love

1
Prostate Cancer — Proceedings from the 2025 Annual ONS Congress 1:27:51

3M ago1:27:51

1:27:51

Dr Rahul Aggarwal and Dr William K Oh and nurse practitioners Ms Monica Averia and Ms Kathleen D Burns discuss the current treatment landscape for prostate cancer and protocols to mitigate and manage treatment-emergent adverse events. NCPD information and select publications here.By Dr. Neil Love

1
Taking a New Path: Evaluating Clinical Data With HER2-Targeted ADCs in Genitourinary, Gastrointestinal, and Gynecological Malignancies 29:36

3M ago29:36

29:36

In this episode, Catherine Fahey, MD, PhD; Alexandra Leary, MD, PhD; Funda Meric-Bernstam, MD; and Zev A. Wainberg, MD, explore the mechanisms of HER2-targeted antibody–drug conjugates (ADCs) and emerging clinical data with these agents across genitourinary, gastrointestinal, and gynecologic cancers. Mechanisms of action of ADCs: how ADCs selective…

1
Chronic Lymphocytic Leukemia — Year in Review Series on Relevant New Datasets and Advances 59:14

3M ago59:14

59:14

Dr Jennifer R Brown from Dana-Farber Cancer Institute in Boston and Prof Paolo Ghia from IRCCS Ospedale San Raffaele in Milano, Italy, summarize clinically relevant research findings and datasets over the past year regarding the treatment of chronic lymphocytic leukemia. CME information and select publications here.…

1
Ovarian Cancer — Proceedings from the 2025 Annual ONS Congress 1:29:57

3M ago1:29:57

1:29:57

Dr David O’Malley and Dr Shannon Westin summarize the clinical treatment landscape for ovarian cancers, supported by clinical perspectives and management strategies from nurse practitioners Ms Courtney Arn and Ms Jennifer Filipi. NCPD information and select publications here.By Dr. Neil Love

1
Immune Thrombocytopenia — A Roundtable Discussion on Current and Future Management Strategies 1:56:57

3M ago1:56:57

1:56:57

Dr Hanny Al-Samkari from Massachusetts General Hospital in Boston, Dr James B Bussel from Weill Cornell School of Medicine in New York, New York, and Prof Nichola Cooper from Hammersmith Hospital Campus in London, United Kingdom, share expert perspectives on the diagnosis of and optimal management strategies for immune thrombocytopenia. CME informa…

1
Antibody-Drug Conjugates for Breast Cancer and Lung Cancer — Proceedings from the 2025 Annual ONS Congress 1:29:57

3M ago1:29:57

1:29:57

Dr Edward B Garon, Dr Tiffany A Traina, and nurse practitioners Ms Marianne J Davies and Ms Marissa Marti-Smith discuss the role of antibody-drug conjugates in the care of patients with breast and lung cancer and strategies to mitigate and manage treatment-emergent adverse events. NCPD information and select publications here.…

1
The Latest Evidence on Targeting B7-H3 in Small Cell Lung Cancer 18:34

3M ago18:34

18:34

In this episode, hear Lauren Byers, MD and Christine Hann, MD share their insights on the latest data regarding new therapies targeting B7-H3 in small cell lung cancer including: Rationale for targeting B7-H3 Overview of the structure of antibody-drug conjugates (ADCs) Results from the phase I/II IDeate-PanTumor01 trial of ifinatamab deruxtecan (I-…

1
Relapsed/Refractory Follicular Lymphoma Part 1 — A Roundtable Discussion on the Selection and Sequencing of Bispecific Antibodies 40:11

3M ago40:11

40:11

Dr Carla Casulo from Wilmot Cancer Institute in Rochester, New York, Dr Matthew Matasar from Rutgers Cancer Institute of New Jersey in New Brunswick and Dr Laurie H Sehn from BC Cancer Centre for Lymphoid Cancer in Vancouver discuss recent updates on available and novel treatment strategies for relapsed/refractory follicular lymphoma. CME informati…

1
The Lay of the Land: Overview of Biology of HER2 in Genitourinary, Gastrointestinal, and Gynecologic Malignancies 14:09

3M ago14:09

14:09

In this episode, Zev A. Wainberg, MD; Funda Meric-Bernstam, MD; Alexandra Leary, MD, PhD; and Catherine Fahey, MD, PhD, explore testing for HER2 alterations and the incidence of HER2-positive disease in the treatment of genitourinary, gastrointestinal, and gynecologic malignancies. HER2 Testing in Advanced Cancers: Recommendations for when and how …

1
Special 2-Part Edition for Oncology Nurses: Bispecific Antibodies in Lymphoma — Part 2 58:21

3M ago58:21

58:21

Nurse practitioner Ms Amy Goodrich from The Sidney Kimmel Comprehensive Care Center in Baltimore, Maryland, presents cases from her practice illustrating the efficacy and safety of bispecific antibodies for non-Hodkin lymphoma. NCPD information and select publications here.By Dr. Neil Love

1
Oncology Nursing Update Special 2-Part Edition: Bispecific Antibodies in Lymphoma — Part 2 58:21

3M ago58:21

58:21

Nurse practitioner Ms Amy Goodrich from The Sidney Kimmel Comprehensive Care Center in Baltimore, Maryland, presents cases from her practice illustrating the efficacy and safety of bispecific antibodies for non-Hodkin lymphoma. NCPD information and select publications here.By Dr. Neil Love

1
Myelofibrosis — An Interview with Dr Raajit K Rampal on Key Presentations from the 66th American Society of Hematology (ASH) Annual Meeting 43:18

4M ago43:18

43:18

Dr Raajit K Rampal from Memorial Sloan Kettering Cancer Center in New York, New York, discusses recent updates on available and novel treatment strategies for myelofibrosis. CME information and select publications here.By Dr. Neil Love

Podcasts Worth a Listen

Chronic Myeloid Leukemia Podcasts

Podcasts Worth a Listen

Quick Reference Guide